- 30 Sep 2025 Form 3 Insider Report for Aptevo Therapeutics Inc. (APVO)

Reporting relationship: 10%+ Owner
Issuer ticker: APVO
Reported as of: 30 Sep 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 03 Oct 2025, 13:59:55 UTC
Prior SEC filing: 29 Sep 2025
Next SEC filing: 03 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Andres Ortiz, Authorized Signatory for Bank of America Corporation

Key filing fact

BANK OF AMERICA CORP /DE/ filed Form 3 for Aptevo Therapeutics Inc. (APVO) on 03 Oct 2025.

Key facts

This page summarizes BANK OF AMERICA CORP /DE/'s Form 3 filing for Aptevo Therapeutics Inc. (APVO).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Oct 2025, 13:59.

Change

Previous filing in this sequence was filed on 29 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (3)

CIK 0000070858 Primary reporting owner

BANK OF AMERICA CORP /DE/

Relationship: 10%+ Owner
Address: BANK OF AMERICA CORPORATE CENTER, 100 N TRYON ST, CHARLOTTE
Signature: /s/ Andres Ortiz, Authorized Signatory for Bank of America Corporation
Signature date: 03 Oct 2025

CIK 0001102113

BANK OF AMERICA NA

Relationship: 10%+ Owner
Address: 100 NORTH TRYON STREET, CHARLOTTE
Signature: /s/ Andres Ortiz, Authorized Signatory for Bank of America N.A.
Signature date: 03 Oct 2025

CIK 0001675365

BOFA SECURITIES, INC.

Relationship: 10%+ Owner
Address: 150 N COLLEGE ST, NC1-028-28-04, CHARLOTTE
Signature: /s/ Andres Ortiz, Authorized Signatory for BofA Securities, Inc.
Signature date: 03 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APVO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 27
Date: 30 Sep 2025
Ownership: See Footnotes
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The 27 common stock shares ("Shares") reported as acquired in Table I represent Shares of APTEVO THERAPEUTICS INC.("the Issuer") beneficially owned by Bank of America N.A. ("BANA"), and BofA Securities, Inc. ("BOFAS"). BANA and BOFAS are wholly owned subsidiaries of Bank of America Corporation ("Bank of America"). The Reporting Owners may be deemed to have temporarily held voting and dispositive power over additional shares as a result of short-term stock borrowings.

Footnote F2

This statement is jointly filed by Bank of America, BANA and BOFAS. Bank of America holds an indirect interest in the securities listed in Table I ("the Securities") by virtue of its indirect ownership of its subsidiaries, BANA and BOFAS.

Footnote F3

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of (ii) a member of any group with respect to the Issuer or any securities of the Issuer.